Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 9 of 9 entries
Sorted by: Best Match Show Resources per page
Clinical and Histopathological Characteristics between Familial and Sporadic Melanoma in Barcelona, Spain.

Journal of clinical & experimental dermatology research

Aguilera P, Malvehy J, Carrera C, Palou J, Puig-Butillé JA, Alòs L, Badenas C, Puig S.
PMID: 25893138
J Clin Exp Dermatol Res. 2014 Sep;5(5):231. doi: 10.4172/2155-9554.1000231.

BACKGROUND: About 6 to 14% of melanoma cases occur in a familial setting. Germline mutations in CDKN2A are detected in 20 to 40% of melanoma families.OBJECTIVE: To characterise the clinical and histopathological characteristics of familial melanoma thus providing more...

Cite
Aguilera P, Malvehy J, Carrera C, et al. Clinical and Histopathological Characteristics between Familial and Sporadic Melanoma in Barcelona, Spain. J Clin Exp Dermatol Res. 2014;5(5):231doi: 10.4172/2155-9554.1000231.
Aguilera, P., Malvehy, J., Carrera, C., Palou, J., Puig-Butillé, J. A., Alòs, L., Badenas, C., & Puig, S. (2014). Clinical and Histopathological Characteristics between Familial and Sporadic Melanoma in Barcelona, Spain. Journal of clinical & experimental dermatology research, 5(5), 231. https://doi.org/10.4172/2155-9554.1000231
Aguilera, Paula, et al. "Clinical and Histopathological Characteristics between Familial and Sporadic Melanoma in Barcelona, Spain." Journal of clinical & experimental dermatology research vol. 5,5 (2014): 231. doi: https://doi.org/10.4172/2155-9554.1000231
Aguilera P, Malvehy J, Carrera C, Palou J, Puig-Butillé JA, Alòs L, Badenas C, Puig S. Clinical and Histopathological Characteristics between Familial and Sporadic Melanoma in Barcelona, Spain. J Clin Exp Dermatol Res. 2014 Sep;5(5):231. doi: 10.4172/2155-9554.1000231. PMID: 25893138; PMCID: PMC4399806.
Copy Download .nbib Format: NLM
Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Maurichi A, Miceli R, Eriksson H, Newton-Bishop J, Nsengimana J, Chan M, Hayes AJ, Heelan K, Adams D, Patuzzo R, Barretta F, Gallino G, Harwood C, Bergamaschi D, Bennett D, Lasithiotakis K, Ghiorzo P, Dalmasso B, Manganoni A, Consoli F, Mattavelli I, Barbieri C, Leva A, Cortinovis U, Espeli V, Mangas C, Quaglino P, Ribero S, Broganelli P, Pellacani G, Longo C, Del Forno C, Borgognoni L, Sestini S, Pimpinelli N, Fortunato S, Chiarugi A, Nardini P, Morittu E, Florita A, Cossa M, Valeri B, Milione M, Pruneri G, Zoras O, Anichini A, Mortarini R, Santinami M.
PMID: 32167862
J Clin Oncol. 2020 May 10;38(14):1591-1601. doi: 10.1200/JCO.19.01902. Epub 2020 Mar 13.

PURPOSE: Thin melanomas (T1; ≤ 1 mm) constitute 70% of newly diagnosed cutaneous melanomas. Regional node metastasis determined by sentinel node biopsy (SNB) is an important prognostic factor for T1 melanoma. However, current melanoma guidelines do not provide clear...

Cite
Maurichi A, Miceli R, Eriksson H, et al. Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram. J Clin Oncol. 2020;38(14):1591-1601doi: 10.1200/JCO.19.01902.
Maurichi, A., Miceli, R., Eriksson, H., Newton-Bishop, J., Nsengimana, J., Chan, M., Hayes, A. J., Heelan, K., Adams, D., Patuzzo, R., Barretta, F., Gallino, G., Harwood, C., Bergamaschi, D., Bennett, D., Lasithiotakis, K., Ghiorzo, P., Dalmasso, B., Manganoni, A., Consoli, F., Mattavelli, I., Barbieri, C., Leva, A., Cortinovis, U., Espeli, V., Mangas, C., Quaglino, P., Ribero, S., Broganelli, P., Pellacani, G., Longo, C., Del Forno, C., Borgognoni, L., Sestini, S., Pimpinelli, N., Fortunato, S., Chiarugi, A., Nardini, P., Morittu, E., Florita, A., Cossa, M., Valeri, B., Milione, M., Pruneri, G., Zoras, O., Anichini, A., Mortarini, R., & Santinami, M. (2020). Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(14), 1591-1601. https://doi.org/10.1200/JCO.19.01902
Maurichi, Andrea, et al. "Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 38,14 (2020): 1591-1601. doi: https://doi.org/10.1200/JCO.19.01902
Maurichi A, Miceli R, Eriksson H, Newton-Bishop J, Nsengimana J, Chan M, Hayes AJ, Heelan K, Adams D, Patuzzo R, Barretta F, Gallino G, Harwood C, Bergamaschi D, Bennett D, Lasithiotakis K, Ghiorzo P, Dalmasso B, Manganoni A, Consoli F, Mattavelli I, Barbieri C, Leva A, Cortinovis U, Espeli V, Mangas C, Quaglino P, Ribero S, Broganelli P, Pellacani G, Longo C, Del Forno C, Borgognoni L, Sestini S, Pimpinelli N, Fortunato S, Chiarugi A, Nardini P, Morittu E, Florita A, Cossa M, Valeri B, Milione M, Pruneri G, Zoras O, Anichini A, Mortarini R, Santinami M. Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram. J Clin Oncol. 2020 May 10;38(14):1591-1601. doi: 10.1200/JCO.19.01902. Epub 2020 Mar 13. PMID: 32167862; PMCID: PMC7213590.
Copy Download .nbib Format: NLM
FRAMe: Familial Risk Assessment of Melanoma-a risk prediction tool to guide CDKN2A germline mutation testing in Australian familial melanoma.

Familial cancer

Holland EA, Lo S, Kelly B, Schmid H, Cust AE, Palmer JM, Drummond M, Hayward NK, Pritchard AL, Mann GJ.
PMID: 32989607
Fam Cancer. 2021 Jul;20(3):231-239. doi: 10.1007/s10689-020-00209-x. Epub 2020 Sep 29.

Germline mutations in CDKN2A greatly increase risk of developing cutaneous melanoma. We have constructed a risk prediction model, Familial Risk Assessment of Melanoma (FRAMe), for estimating the likelihood of carrying a heritable CDKN2A mutation among Australian families, where the...

Cite
Holland EA, Lo S, Kelly B, et al. FRAMe: Familial Risk Assessment of Melanoma-a risk prediction tool to guide CDKN2A germline mutation testing in Australian familial melanoma. Fam Cancer. 2020;20(3):231-239doi: 10.1007/s10689-020-00209-x.
Holland, E. A., Lo, S., Kelly, B., Schmid, H., Cust, A. E., Palmer, J. M., Drummond, M., Hayward, N. K., Pritchard, A. L., & Mann, G. J. (2021). FRAMe: Familial Risk Assessment of Melanoma-a risk prediction tool to guide CDKN2A germline mutation testing in Australian familial melanoma. Familial cancer, 20(3), 231-239. https://doi.org/10.1007/s10689-020-00209-x
Holland, Elizabeth A, et al. "FRAMe: Familial Risk Assessment of Melanoma-a risk prediction tool to guide CDKN2A germline mutation testing in Australian familial melanoma." Familial cancer vol. 20,3 (2021): 231-239. doi: https://doi.org/10.1007/s10689-020-00209-x
Holland EA, Lo S, Kelly B, Schmid H, Cust AE, Palmer JM, Drummond M, Hayward NK, Pritchard AL, Mann GJ. FRAMe: Familial Risk Assessment of Melanoma-a risk prediction tool to guide CDKN2A germline mutation testing in Australian familial melanoma. Fam Cancer. 2021 Jul;20(3):231-239. doi: 10.1007/s10689-020-00209-x. Epub 2020 Sep 29. PMID: 32989607.
Copy Download .nbib Format: NLM
Update in genetic susceptibility in melanoma.

Annals of translational medicine

Potrony M, Badenas C, Aguilera P, Puig-Butille JA, Carrera C, Malvehy J, Puig S.
PMID: 26488006
Ann Transl Med. 2015 Sep;3(15):210. doi: 10.3978/j.issn.2305-5839.2015.08.11.

Melanoma is the most deadly of the common skin cancers and its incidence is rapidly increasing. Approximately 10% of cases occur in a familial context. To date, cyclin-dependent kinase inhibitor 2A (CDKN2A), which was identified as the first melanoma...

Cite
Potrony M, Badenas C, Aguilera P, et al. Update in genetic susceptibility in melanoma. Ann Transl Med. 2015;3(15):210doi: 10.3978/j.issn.2305-5839.2015.08.11.
Potrony, M., Badenas, C., Aguilera, P., Puig-Butille, J. A., Carrera, C., Malvehy, J., & Puig, S. (2015). Update in genetic susceptibility in melanoma. Annals of translational medicine, 3(15), 210. https://doi.org/10.3978/j.issn.2305-5839.2015.08.11
Potrony, Miriam, et al. "Update in genetic susceptibility in melanoma." Annals of translational medicine vol. 3,15 (2015): 210. doi: https://doi.org/10.3978/j.issn.2305-5839.2015.08.11
Potrony M, Badenas C, Aguilera P, Puig-Butille JA, Carrera C, Malvehy J, Puig S. Update in genetic susceptibility in melanoma. Ann Transl Med. 2015 Sep;3(15):210. doi: 10.3978/j.issn.2305-5839.2015.08.11. PMID: 26488006; PMCID: PMC4583600.
Copy Download .nbib Format: NLM
Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom.

Hereditary cancer in clinical practice

Harland M, Cust AE, Badenas C, Chang YM, Holland EA, Aguilera P, Aitken JF, Armstrong BK, Barrett JH, Carrera C, Chan M, Gascoyne J, Giles GG, Agha-Hamilton C, Hopper JL, Jenkins MA, Kanetsky PA, Kefford RF, Kolm I, Lowery J, Malvehy J, Ogbah Z, Puig-Butille JA, Orihuela-Segalés J, Randerson-Moor JA, Schmid H, Taylor CF, Whitaker L, Bishop DT, Mann GJ, Newton-Bishop JA, Puig S.
PMID: 25780468
Hered Cancer Clin Pract. 2014 Nov 20;12(1):20. doi: 10.1186/1897-4287-12-20. eCollection 2014.

BACKGROUND: Mutations in the CDKN2A and CDK4 genes predispose to melanoma. From three case-control studies of cutaneous melanoma, we estimated the prevalence and predictors of these mutations for people from regions with widely differing latitudes and melanoma incidence.METHODS: Population-based...

Cite
Harland M, Cust AE, Badenas C, et al. Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom. Hered Cancer Clin Pract. 2014;12(1):20doi: 10.1186/1897-4287-12-20.
Harland, M., Cust, A. E., Badenas, C., Chang, Y. M., Holland, E. A., Aguilera, P., Aitken, J. F., Armstrong, B. K., Barrett, J. H., Carrera, C., Chan, M., Gascoyne, J., Giles, G. G., Agha-Hamilton, C., Hopper, J. L., Jenkins, M. A., Kanetsky, P. A., Kefford, R. F., Kolm, I., Lowery, J., Malvehy, J., Ogbah, Z., Puig-Butille, J. A., Orihuela-Segalés, J., Randerson-Moor, J. A., Schmid, H., Taylor, C. F., Whitaker, L., Bishop, D. T., Mann, G. J., Newton-Bishop, J. A., & Puig, S. (2014). Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom. Hereditary cancer in clinical practice, 12(1), 20. https://doi.org/10.1186/1897-4287-12-20
Harland, Mark, et al. "Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom." Hereditary cancer in clinical practice vol. 12,1 (2014): 20. doi: https://doi.org/10.1186/1897-4287-12-20
Harland M, Cust AE, Badenas C, Chang YM, Holland EA, Aguilera P, Aitken JF, Armstrong BK, Barrett JH, Carrera C, Chan M, Gascoyne J, Giles GG, Agha-Hamilton C, Hopper JL, Jenkins MA, Kanetsky PA, Kefford RF, Kolm I, Lowery J, Malvehy J, Ogbah Z, Puig-Butille JA, Orihuela-Segalés J, Randerson-Moor JA, Schmid H, Taylor CF, Whitaker L, Bishop DT, Mann GJ, Newton-Bishop JA, Puig S. Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom. Hered Cancer Clin Pract. 2014 Nov 20;12(1):20. doi: 10.1186/1897-4287-12-20. eCollection 2014. PMID: 25780468; PMCID: PMC4361137.
Copy Download .nbib Format: NLM
Reply to E. Hindié.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Maurichi A, Miceli R, Eriksson H, Newton-Bishop J, Nsengimana J, Chan M, Hayes AJ, Heelan K, Adams D, Patuzzo R, Barretta F, Gallino G, Harwood C, Bergamaschi D, Bennett D, Lasithiotakis K, Ghiorzo P, Dalmasso B, Manganoni A, Consoli F, Mattavelli I, Barbieri C, Leva A, Cortinovis U, Espeli V, Mangas C, Quaglino P, Ribero S, Broganelli P, Pellacani G, Longo C, Del Forno C, Borgognoni L, Sestini S, Pimpinelli N, Fortunato S, Chiarugi A, Nardini P, Morittu E, Florita A, Cossa M, Valeri B, Milione M, Pruneri G, Zoras O, Anichini A, Mortarini R, Santinami M.
PMID: 32701413
J Clin Oncol. 2020 Sep 20;38(27):3238-3240. doi: 10.1200/JCO.20.01460. Epub 2020 Jul 23.

No abstract available.

Cite
Maurichi A, Miceli R, Eriksson H, et al. Reply to E. Hindié. J Clin Oncol. 2020;38(27):3238-3240doi: 10.1200/JCO.20.01460.
Maurichi, A., Miceli, R., Eriksson, H., Newton-Bishop, J., Nsengimana, J., Chan, M., Hayes, A. J., Heelan, K., Adams, D., Patuzzo, R., Barretta, F., Gallino, G., Harwood, C., Bergamaschi, D., Bennett, D., Lasithiotakis, K., Ghiorzo, P., Dalmasso, B., Manganoni, A., Consoli, F., Mattavelli, I., Barbieri, C., Leva, A., Cortinovis, U., Espeli, V., Mangas, C., Quaglino, P., Ribero, S., Broganelli, P., Pellacani, G., Longo, C., Del Forno, C., Borgognoni, L., Sestini, S., Pimpinelli, N., Fortunato, S., Chiarugi, A., Nardini, P., Morittu, E., Florita, A., Cossa, M., Valeri, B., Milione, M., Pruneri, G., Zoras, O., Anichini, A., Mortarini, R., & Santinami, M. (2020). Reply to E. Hindié. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(27), 3238-3240. https://doi.org/10.1200/JCO.20.01460
Maurichi, Andrea, et al. "Reply to E. Hindié." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 38,27 (2020): 3238-3240. doi: https://doi.org/10.1200/JCO.20.01460
Maurichi A, Miceli R, Eriksson H, Newton-Bishop J, Nsengimana J, Chan M, Hayes AJ, Heelan K, Adams D, Patuzzo R, Barretta F, Gallino G, Harwood C, Bergamaschi D, Bennett D, Lasithiotakis K, Ghiorzo P, Dalmasso B, Manganoni A, Consoli F, Mattavelli I, Barbieri C, Leva A, Cortinovis U, Espeli V, Mangas C, Quaglino P, Ribero S, Broganelli P, Pellacani G, Longo C, Del Forno C, Borgognoni L, Sestini S, Pimpinelli N, Fortunato S, Chiarugi A, Nardini P, Morittu E, Florita A, Cossa M, Valeri B, Milione M, Pruneri G, Zoras O, Anichini A, Mortarini R, Santinami M. Reply to E. Hindié. J Clin Oncol. 2020 Sep 20;38(27):3238-3240. doi: 10.1200/JCO.20.01460. Epub 2020 Jul 23. PMID: 32701413; PMCID: PMC7499609.
Copy Download .nbib Format: NLM
Growth-Curve Modeling of Nevi With a Peripheral Globular Pattern.

JAMA dermatology

Bajaj S, Dusza SW, Marchetti MA, Wu X, Fonseca M, Kose K, Brito J, Carrera C, Martins de Silva VP, Malvehy J, Puig S, Yagerman S, Liebman TN, Scope A, Halpern AC, Marghoob AA.
PMID: 26287475
JAMA Dermatol. 2015 Dec 01;151(12):1338-1345. doi: 10.1001/jamadermatol.2015.2231.

IMPORTANCE: Although nevi with a peripheral rim of globules (peripheral globular nevi [PGN]) observed with dermoscopy are associated with enlarging melanocytic nevi, their actual growth dynamics remain unknown. Because change is a sensitive but nonspecific marker for melanoma, beginning...

Cite
Bajaj S, Dusza SW, Marchetti MA, et al. Growth-Curve Modeling of Nevi With a Peripheral Globular Pattern. JAMA Dermatol. 2015;151(12):1338-1345doi: 10.1001/jamadermatol.2015.2231.
Bajaj, S., Dusza, S. W., Marchetti, M. A., Wu, X., Fonseca, M., Kose, K., Brito, J., Carrera, C., Martins de Silva, V. P., Malvehy, J., Puig, S., Yagerman, S., Liebman, T. N., Scope, A., Halpern, A. C., & Marghoob, A. A. (2015). Growth-Curve Modeling of Nevi With a Peripheral Globular Pattern. JAMA dermatology, 151(12), 1338-1345. https://doi.org/10.1001/jamadermatol.2015.2231
Bajaj, Shirin, et al. "Growth-Curve Modeling of Nevi With a Peripheral Globular Pattern." JAMA dermatology vol. 151,12 (2015): 1338-1345. doi: https://doi.org/10.1001/jamadermatol.2015.2231
Bajaj S, Dusza SW, Marchetti MA, Wu X, Fonseca M, Kose K, Brito J, Carrera C, Martins de Silva VP, Malvehy J, Puig S, Yagerman S, Liebman TN, Scope A, Halpern AC, Marghoob AA. Growth-Curve Modeling of Nevi With a Peripheral Globular Pattern. JAMA Dermatol. 2015 Dec 01;151(12):1338-1345. doi: 10.1001/jamadermatol.2015.2231. PMID: 26287475; PMCID: PMC5483973.
Copy Download .nbib Format: NLM
Review of Clinical Evidence over 10 Years on Prevention and Treatment of a Film-Forming Medical Device Containing Photolyase in the Management of Field Cancerization in Actinic Keratosis.

Dermatology and therapy

Puig S, Granger C, Garre A, Trullàs C, Sanmartin O, Argenziano G.
PMID: 30968311
Dermatol Ther (Heidelb). 2019 Jun;9(2):259-270. doi: 10.1007/s13555-019-0294-1. Epub 2019 Apr 09.

Actinic keratosis (AK) is a common pathology that afflicts sun-exposed areas of the skin. It predominantly affects older and fair-skinned individuals suggesting an accumulative damage attributable to chronic sun exposure. The prevalence of AK has risen in the past...

Cite
Puig S, Granger C, Garre A, et al. Review of Clinical Evidence over 10 Years on Prevention and Treatment of a Film-Forming Medical Device Containing Photolyase in the Management of Field Cancerization in Actinic Keratosis. Dermatol Ther (Heidelb). 2019;9(2):259-270doi: 10.1007/s13555-019-0294-1.
Puig, S., Granger, C., Garre, A., Trullàs, C., Sanmartin, O., & Argenziano, G. (2019). Review of Clinical Evidence over 10 Years on Prevention and Treatment of a Film-Forming Medical Device Containing Photolyase in the Management of Field Cancerization in Actinic Keratosis. Dermatology and therapy, 9(2), 259-270. https://doi.org/10.1007/s13555-019-0294-1
Puig, Susana, et al. "Review of Clinical Evidence over 10 Years on Prevention and Treatment of a Film-Forming Medical Device Containing Photolyase in the Management of Field Cancerization in Actinic Keratosis." Dermatology and therapy vol. 9,2 (2019): 259-270. doi: https://doi.org/10.1007/s13555-019-0294-1
Puig S, Granger C, Garre A, Trullàs C, Sanmartin O, Argenziano G. Review of Clinical Evidence over 10 Years on Prevention and Treatment of a Film-Forming Medical Device Containing Photolyase in the Management of Field Cancerization in Actinic Keratosis. Dermatol Ther (Heidelb). 2019 Jun;9(2):259-270. doi: 10.1007/s13555-019-0294-1. Epub 2019 Apr 09. PMID: 30968311; PMCID: PMC6522584.
Copy Download .nbib Format: NLM
Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formation.

Developmental cell

Campbell NR, Rao A, Hunter MV, Sznurkowska MK, Briker L, Zhang M, Baron M, Heilmann S, Deforet M, Kenny C, Ferretti LP, Huang TH, Perlee S, Garg M, Nsengimana J, Saini M, Montal E, Tagore M, Newton-Bishop J, Middleton MR, Corrie P, Adams DJ, Rabbie R, Aceto N, Levesque MP, Cornell RA, Yanai I, Xavier JB, White RM.
PMID: 34529939
Dev Cell. 2021 Oct 25;56(20):2808-2825.e10. doi: 10.1016/j.devcel.2021.08.018. Epub 2021 Sep 15.

Melanomas can have multiple coexisting cell states, including proliferative (PRO) versus invasive (INV) subpopulations that represent a "go or grow" trade-off; however, how these populations interact is poorly understood. Using a combination of zebrafish modeling and analysis of patient...

Cite
Campbell NR, Rao A, Hunter MV, et al. Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formation. Dev Cell. 2021;56(20):2808-2825.e10doi: 10.1016/j.devcel.2021.08.018.
Campbell, N. R., Rao, A., Hunter, M. V., Sznurkowska, M. K., Briker, L., Zhang, M., Baron, M., Heilmann, S., Deforet, M., Kenny, C., Ferretti, L. P., Huang, T. H., Perlee, S., Garg, M., Nsengimana, J., Saini, M., Montal, E., Tagore, M., Newton-Bishop, J., Middleton, M. R., Corrie, P., Adams, D. J., Rabbie, R., Aceto, N., Levesque, M. P., Cornell, R. A., Yanai, I., Xavier, J. B., & White, R. M. (2021). Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formation. Developmental cell, 56(20), 2808-2825.e10. https://doi.org/10.1016/j.devcel.2021.08.018
Campbell, Nathaniel R, et al. "Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formation." Developmental cell vol. 56,20 (2021): 2808-2825.e10. doi: https://doi.org/10.1016/j.devcel.2021.08.018
Campbell NR, Rao A, Hunter MV, Sznurkowska MK, Briker L, Zhang M, Baron M, Heilmann S, Deforet M, Kenny C, Ferretti LP, Huang TH, Perlee S, Garg M, Nsengimana J, Saini M, Montal E, Tagore M, Newton-Bishop J, Middleton MR, Corrie P, Adams DJ, Rabbie R, Aceto N, Levesque MP, Cornell RA, Yanai I, Xavier JB, White RM. Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formation. Dev Cell. 2021 Oct 25;56(20):2808-2825.e10. doi: 10.1016/j.devcel.2021.08.018. Epub 2021 Sep 15. PMID: 34529939; PMCID: PMC8551056.
Copy Download .nbib Format: NLM
Showing 1 to 9 of 9 entries